Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine > Result Summary for 208136/018

Result Summary for 208136/018

Result Summary

Protocol ID:	208136/018
Clinical Study ID:	208136/018 (MeMuRu-OKA-018)
Official Title:	Study to evaluate immunogenicity and safety of GSK Bios’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Bios’ Priorix™ and Varilrix™ vaccines
Phase:	Phase 3
Study Indications or Diseases:	Measles-Mumps-Rubella-Varicella Vaccine
Generic Name:	Combined Measles, Mumps, Rubella, Varicella Vaccine
Trade/Product Name:	Priorix-Tetra;Priorix-Tetra
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Goh P et al. (2007) Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 35(5):326-333. Goh F et al. Safety and immunogenicity of a two-dose measles-mumps-rubella-varicella (MMRV) vaccine in healthy children at 9 and 12 months of age. Abstract presented at the 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Valencia, Spain, 18-20 May 2005. Sohita D et al. (2008) Live Attenuated Measles, Mumps, Rubella, and Varicella Zoster Virus Vaccine (Priorix-Tetra). Pediatric Drugs. 10(5):337-347. Kreth HW et al. (2008) Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix™). Biodrugs. 22(6):387-402. Knuf M et al. (2008) A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 44(4):279-292.